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over other LAIs in terms of discontinuation due to AEs. This study provides support 
for formulary decision-making in the absence of head-to-head data.
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Objectives: In recent years workplace mobbing attracts notice in public and sci-
ence. Victims of workplace mobbing frequently suffer from depressions, somatic 
symptoms, may develop alcoholism or other substance abuse disorders and show 
increased risk of suicidal behavior. The aim of this study was to calculate the 
number of patients with a workspace mobbing documentation and their diagnosis 
profile in general practices in Germany between 2003 and 2012 based on the data 
from a large epidemiological database. MethOds: This retrospective study ana-
lysed longitudinal routine care data collected by general practitioners in Germany 
(IMS® Disease Analyzer). Data from patients with notice as workplace mobbing 
(N= 2653) and without such notice (N= 2653) from 199 general medical practices 
in Germany (Disease Analyzer database; 01/2003 to 12/2012) were matched for 
age (41 ± 13 years), gender (male: 33%), health insurance (private: 5%) and retro-
spectively analyzed. Odds Ratio (OR; Logistic regression) for depression, anxiety, 
somatoform disorder, migraine and sleep disorder (follow-up: 3 years) were calcu-
lated. Results: In 2003, 24 (projected to national level: 2448) patients were docu-
mented as mobbing victims; this number continuously increased to 429 (projected 
to national level: 43758) in 2012. Shares of female patients and mean age have not 
significantly changed from 2003 till 2012. In workspace mobbing persons there 
was a increased risk of depression (OR: 4.11, p< 0.001), anxiety (OR: 2.76, p< 0.001), 
somatoform disorder (OR: 3.51, p< 0.001), migraine (OR: 1.41, p= 0.003) and sleep 
disorder (OR: 2.32, p< 0.001). cOnclusiOns: This retrospective database analysis 
showed that experience of workspace mobbing was associated with increased 
prevalence of psychiatric and neurological problems. Further research is required 
to understand this complex issue.
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Objectives: As the cultural adaptation process of PROs (Patient Reported 
Outcome instruments), every version of PROs should be validated. However, little 
is known whether those validated PROs are identical in terms of the test perfor-
mance (operating characteristics). In this study, we investigated PHQ-9 (Patient 
Health Questionnaire-9 for depression) using the meta-analysis. MethOds: We 
searched PubMed for studies examining diagnostic accuracy of PHQ-9. Then we 
extracted or retrieved 2 x 2 data from each study and meta-analysis was performed 
using Bivariate model (Reitsma et al. 2005). As the language versions of PHQ-9 
and regions where the studies were conducted would be potential confounding 
factors, we performed meta-regression. Bivariate meta-analysis of the subgroup 
(region, language) was explored. Results: Twenty-eight studies met our inclu-
sion criteria. Univariate meta-regression showed that all the covariates assessed 
such as language, region significantly contributed to the heterogeneity of sensi-
tivity (I^2= 82.7) and specificity (I^2= 92.5) among the studies. Meta-analysis of 
subgroup of the regions and languages was made using bivariate model; studies 
conducted in North America (6 studies), Europe (13 studies), or Asia & others 
(9 studies); LogitSe of North America, Europe and Asia& other were 1.66, 1.45, 
and 1.48, respectively. Logit Sp of these regions was 1.87, 1.90 and 2.22, respec-
tively. cOnclusiOns: Results suggest that operational characteristics would 
influenced by the regions, language version of PHQ-9. Therefore, when considering 
a multiregional study using PHQ-9 as screening tool, there would be a chance of 
some imbalance among regions. Therefore, before initiation of the clinical studies, 
efforts need to minimize the heterogeneity of the definite diagnosis, e.g. training 
to the investigators, or central diagnosis.
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Objectives: To investigate factors associated with changes in attention-defi-
cit/hyperactivity disorder (ADHD) symptom severity and quality of life (QoL) in 
patients who were responders and stable on their pharmacotherapy at study 
entry. MethOds: “AUTOR” is a European prospective, observational study inves-
tigating factors associated with ADHD severity changes during a 2-year follow-up 
period in patients aged 6-17 years. At baseline, patients had received the same 
pharmacotherapy for 3-8 months and had a Clinical Global Impression (CGI)-ADHD-
Severity score of mild or lower and a CGI-ADHD-improvement score of improved/
very much improved since treatment initiation. Data were collected at naturally 
occurring visits coinciding with observation windows (postbaseline): 0, 3, 6, 9, 12, 
18, and 24 months, and ±6 weeks. ADHD symptom severity worsening was defined 
as a ≥ 2-point increase from baseline in CGI-ADHD-Severity score. The Child Health 
Profile-Child Edition (CHIP-CE) was used to measure QoL. Multivariate logistic 
regression was used to assess the association of different factors with changes 
in ADHD severity at any time postbaseline. Mixed-model repeated measures 
(MMRM) regression was used to estimate adjusted differences between treatments. 
Propensity scoring was used to adjust for imbalanced covariates before treatment 
comparisons. Results: Data were analyzed from 704 patients (mean [standard 
Objectives: In 2012, ivabradine was centrally approved by the EMA for Chronic 
Heart Failure treatment. Through ivabradine NICE and HAS decisions analysis, the 
objective of this policy research is to illustrate the divergence of HTA decisions 
despite a consistent efficacy, effectiveness and economics information. MethOds: 
NICE and HAS reports were fully reviewed with a focus on decisions outcomes. 
Then, convergences and divergences between HAS and NICE decisions were high-
lighted. Results: NICE recommended for use ivabradine for patient with NYHA 
class II to IV with systolic dysfunction, with sinus rhythm with a heart rate ≥ 75 
bpm, in combination with standard therapy or when beta-blocker therapy is con-
traindicated or not tolerated, and with a left ventricular ejection fraction ≤ 35%. 
Decision made by NICE was mainly based on results of one subgroup defined post 
hoc on the request of EMA. HAS rated the actual benefit of ivabradine as impor-
tant for the labelled indication, nevertheless HAS distinguishes 2 subpopulations: 
one with minor improvement of actual benefit - patient with NYHA class II to III 
with systolic dysfunction in sinus rhythm with the heart rate ≥ 77 bpm and in 
which beta-blockers are contraindicated or not tolerated- for the other patients, 
HAS stated that ivabradine does not provide improvement in actual benefit. HAS 
based its decision mainly on the results of one subgroup defined a priori in which 
ivabradine was superior to each individual components of the primary combined 
endpoint. cOnclusiOns: While EUnetHTA attempts to provide a coordinated opin-
ion on comparative effectiveness, HTA decisions continue to be divergent across 
Europe. Ivabradine NICE and HAS decisions divergences exemplify once more the 
inconsistency of HTA decisions and highlight the obstacle for the establishment 
of a jointed EUHTA body.
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Objectives: The primary objective of this study was to report the clinical out-
comes, i.e. routine calculation of time in therapeutic range (TTR), bleed events and 
thromboembolic events for patients on warfarin in a general practice following 
the introduction of quality improvement initiatives. A secondary objective was 
to estimate the cost of care of these patients managed from the perspective of 
the general practice. MethOds: Clinical data were analysed annually using a 
General Practice database, adapted to allow calculation of TTR for all patients pre-
scribed warfarin for the years 2009 (baseline), to 2011 (Year 2). Decision trees were 
constructed to reflect typical episodes of care for patients with atrial fibrillation 
(AF). Resource use and unit cost data were applied to each node in the decision 
tree. The probabilities of events occurring were derived from the literature and 
expert clinical opinion. A 60% TTR was used as a reference criterion for patient 
outcomes. Ethical approval for the study was obtained. Analysis was performed 
in SPSS®. Results: The TTR at baseline was 54%, rising to 61% in Year 1 and 63% 
in Year 2. One patient suffered a haemorrhagic stroke in the baseline year (TTR 
71%), and in the same year there were 4 thromboembolic events. No major haem-
orrhagic or thromboembolic events have been recorded in the follow-up years. 
The median cost per patient with AF was € 276 (using a median of 12 INR tests per 
annum). cOnclusiOns: The introduction of routine assessment of TTR in the 
practice has resulted in a significant improvement in care as demonstrated by the 
rise in TTR values, and adherence to international best-practice criteria. Clinically 
significant outcomes on patient care are also evident with the absence of major 
bleed events or thromboembolic breakthrough events. The study highlights the 
feasibility and benefits of enhanced care at local level.
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Objectives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia. However, approximately 
50% of patients with schizophrenia miss taking > 30% of their medication, there-
fore the use of long-acting injectable (LAI) formulations is an important option for 
patients partially or non-adherent to oral formulations. This study aimed to com-
pare LAIs in terms of efficacy and safety. MethOds: A systematic literature review 
in PubMed, EMBASE, Cochrane, PsychINFO and conference abstracts was conducted 
to identify relevant randomized controlled trials of LAIs in maintenance treatment 
in schizophrenia. Selection criteria included long-term follow-up, stable patients 
and minimamilly one LAI treatment arm. The primary efficacy outcome was relapse 
rate; rate of discontinuation due to treatment-related adverse events (AEs) was also 
considered in this analysis. Data on discontinuation parameters were analyzed by 
applying a MTC competing risks model appropriate for multinomial distribution 
of data using WinBUGS. Results: Six trials (study follow-up from 24 to 53 weeks) 
were identified, allowing comparisons of aripiprazole (oral and LAI), risperidone 
LAI, paliperidone LAI, olanzapine (oral and LAI), haloperidol LAI and placebo. The 
total patient number was 3402, of which 534 (16%) received aripiprazole. Compared 
to placebo the risk of relapse was the smallest for aripiprazole LAI (mean hazard 
ratio [HR]= 0.26, 95% confidence interval [CI] 0.12-0.50) and risperidone LAI (HR= 0.29, 
95% 0.05-0.83). The risk of discontinuation due to AEs was lower than placebo for 
aripiprazole LAI (HR= 0.72) and higher than placebo for the other LAIs (paliperidone 
LAI: HR= 5.08, risperidone LAI: HR= 12.06, olanzapine LAI: HR= 6.58, haloperidol LAI: 
HR= 4.19). cOnclusiOns: The MTC suggests that aripiprazole LAI is at least as effi-
cacious in the management of relapse prevention as other LAIs with an advantage 
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Objectives: To assess health care professional’s judgments on economic con-
sequences of prescribed medical interventions and their responsiveness of 
different health care policy measures aiming for increasing their cost-conscious-
ness. MethOds: The design encompassed the nation-wide-cross-sectional hier-
archical levels of health care facilities across the geographical regions. Authors 
used validated and standardized Likert scale of Health Economic Awareness (HEA) 
adjusted for local setting to evaluate health care professionals by face-to-face inter-
views. The questionnaire comprehended clinician’sattitudes on: Clinical-Decision-
Making-Alternative-Interventions (CDMAI); Quality-of –Health-care (QHC); and 
Cost-Containment-Policy (CCP). This survey was conducted in two waves before 
and after policy intervention in 40 hospitals and primary care facilities in fifteen 
cities in Serbia from January 2010-December 2012. A total of 649 participants were 
interviewed before the intervention and 651 after the intervention. Core Republican 
Health Insurance Fund adopted and disseminated the package of cost containment 
measures through the Nation-wide pharmacoeconomic guidelines which princi-
pally targeted at prescribers. Pharmacists, physicians and dentists were examined 
by the scores of CDMAI, QHC, CCP and HEA. Results: Pharmacists and dentists 
had a higher average score (mean±s.d.) of CDMAI by the pharmacists (1.200±0.421) 
and the dentists (1.195±0.560) than the score of physicians (1.017±0.453). Dentists 
had the highest average score of CCP (2.127±0.598) and then the score of physicians 
(1.976±0.529). The score of pharmacists was the lowest (1.854±0.461).There were no 
impacts of the interventions on the professional behaviors regarding the scores 
of QHQ, CDMAI, CCP, and HEA. cOnclusiOns: Health economic awareness has 
differed substantially among of different health care professionals. Health policy 
measures were implemented to reduce non-cost-effective prescribing behaviors 
but the effects are non-clear-cut evidences. This experimental study is a pioneering 
effort in the wider Balkans region.
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Objectives: To assess the efficacy and safety of agomelatine using pharma-
covigilance during 12-week follow-up. MethOds: Agomelatine 25-50 mg was pre-
scribed open label to patients with depressive disorders diagnosed by psychiatrists 
based on DSM-IV/ICD-10 criteria. Treatment options were intent-to-treat. All 480 
patients, including 97 elderly patients were followed up at week 2 if dose titra-
tion was necessary. Efficacy was assessed using Montgomery-Äsberg Depression 
Rating Scale(MÄDRS) and clinical global impression of improvement (CGI-I) and of 
severity (CGI-S) scales, at weeks 2, 6, and 12. Data on adverse effects and for reports 
were gathered through patient interviews. Results: Of 480 patients, 20-86 years 
(mean[SD] 49.6[14.5]), 247(51.5%) were men and 97(20.2%) were elderly (65 to 86; 
mean[SD] 71.1[5.0]). Among all patients, 225(46.9%) and 255(53.1%) were depressed 
with a single episode and recurrent episodes. Patients with recurrent episodes were 
taking various classes of antidepressants, including selective serotonin reuptake 
inhibitors in 328(50.9%) patients. Generalized anxiety disorder was a concurrent 
diagnosis in 95(24.3%) of patients. The respective mean(SD) baseline CGI-S, CGI-I, 
and MADRS scores of 3.90(0.68), 4.15(0.76), and 22.59(3.77) were reduced to 2.1(0.31), 
1.11(0.37), and 9.19(2.03), with respective reductions in mean(SD; 95% CI) scores of 
1.78(0.75;1.72-1.85), 2.98(0.78;2.91-3.05), and 13.39(4.36; 13.00-13.78). Similar efficacy 
was evidenced for elderly depressed patients (N= 97), in whom mean(SD) MADRS 
score at baseline 22.37(4.79) was consistently significantly reduced to 14.61(3.04), 
10.76(3.04), and 8.72(1.91) at weeks 2, 6, and 12, respectively. After 12 weeks, over-
all remission (MADRS score < 10) was seen in 68.4% of patients with moderate to 
severe (MADRS > 25) depression and in 73.4% of elderly depressed patients. The 
mild adverse events reported were dizziness(9.5%), headache(7.4%), difficulty sleep-
ing(6.3%), and nausea(3.1%). There were no cases reported of alanine transaminase 
levels three times above upper limit of normal. cOnclusiOns: Agomelatine has 
proven to be a safe and effective new antidepressant in intent-to-treat analysis of 
depressed, including elderly, patients in daily clinical practice in Thailand.
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Objectives: Second generation antipsychotics (SGA) are associated with increased 
risk of metabolic side effects. A systematic literature review and mixed treatment 
comparisons (MTC) were performed to assess the efficacy and the metabolic side 
effects of antipsychotics, and more especially to compare lurasidone to other widely 
used antipsychotics in patient with acute schizophrenia. MethOds: This review 
included short-term (≤ 12 weeks) randomised controlled trials (RCTs) in patients 
with an acute phase of schizophrenia. The literature search was based on the 
NICE guidelines on treatment for schizophrenia published in 2010. A systematic 
search in the most comprehensive medical databases of peer-reviewed articles 
(MEDLINE, EMBASE, CENTRAL) was conducted until June 2012 to update the evi-
dence. In addition to lurasidone, eight comparators were considered: amisulpride, 
aripiprazole, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone and pla-
cebo. A Bayesian ramdom effect MTC was performed on efficacy outcomes (PANSS 
total score and CGI-S score) and metabolic side effects (weight, triglycerides, total 
cholesterol level and fasting glucose level). Results: Thirty-nine RCTs involving 
12,721 patients were included. Results showed that lurasidone had similar efficacy 
deviation] age 10.7 [2.75] years, 99% Caucasian, 82% male, 76% combined ADHD 
subtype). Variables associated with worsening severity were: baseline parental 
occupation (P= .003), poorer school outcomes (P< .001), and use of psychoeducation 
(P= .004). Initial use of nonstimulants (vs. stimulants) was associated with significant 
improvement on the CHIP-CE total score at 3 months and 9-24 months postbaseline. 
The estimated adjusted difference between treatments was −6.0 (95% confidence 
interval: −7.9, −4.1) at 24 months postbaseline. cOnclusiOns: In this observational 
study, worsening of ADHD symptoms was associated with initial use of psychoe-
ducation, parental occupation, and poorer school outcomes. Initial treatment with 
nonstimulants (vs. stimulants) was associated with improved QoL.
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Objectives: To assess the efficacy of a cognitive enhancer, donepezil, as an adju-
vant treatment to antipsychotics on clinical outcomes of schizophrenia. MethOds: 
Systematic review with meta-analysis to obtain appropriate evidence from rand-
omized clinical trials (RCTs) on the efficacy of donepezil plus antipsychotics versus 
placebo plus antipsychotics in patients diagnosed with schizophrenia for the follow-
ing outcomes: general psychopathology, positive/negative symptoms, and depres-
sive symptoms. Effect size estimates corrected for small sample size trials (Hedges’ 
g) were calculated for parallel trials and cross-over trials. Negative values for Hedges’ 
g denote an effect favouring the combined treatment. When needed, values for the 
cross-over correlation were imputed from available individual data to obtain the 
Hedges’ g estimates. The individual estimates were pooled with a random-effects 
meta-analysis. Results: Seven trials (4 cross-over, 3 parallel) were included. Four 
trials provided data on the Positive and Negative Syndrome Scale (PANSS) for total 
and general psychopathology scores. Three trials provided data for PANSS positive 
scores and 5 trials provided data for PANSS negative scores. Three trials provided 
data on depression scores. The combined treatment did not show differences in 
any of the assessed outcomes: PANSS total scores (g = -0.57, 95% CI = -2.11 to 0.96, 
I2 = 67%); PANSS General Psychopathology scores (g = -0.20, 95% CI = -0.74 to 0.34, 
I2 = 0%); PANSS positive symptoms (g = -0.06, 95% CI = -0.73 to 0.60, I2 = 0%); PANSS 
negative symptoms (g = -0.43, 95% CI = -1.98 to 1.12, I2 = 86%); depression scores (g = 
-0.35, 95% CI = -1.20 to 0.49, I2 = 0%). cOnclusiOns: The combination of donepezil 
with antipsychotic treatment does not improve clinical outcomes in schizophrenia.
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Objectives: Levomilnacipran (1S,2R-milnacipran) is a potent and selective seroto-
nin and norepinephrine reuptake inhibitor (SNRI) with approximately 2-fold greater 
potency for reuptake inhibition of norepinephrine than serotonin. Levomilnacipran 
SR is in late-stage clinical development for the treatment of major depressive dis-
order (MDD) in adults. A pooled analysis of Phase III studies was conducted to 
evaluate the effects of levomilnacipran SR treatment on functional health and 
well-being. MethOds: Pooled analysis of three double-blind, placebo-controlled, 
Phase III randomized clinical trials (Clinicaltrials.gov #NCT00969709, NCT00969150, 
NCT01034462), which included one fixed-dose (levomilnacipran SR 40, 80 or 120 mg/
day or placebo) and two flexible-dose (levomilnacipran SR 40-120 mg/day or placebo) 
studies that included the acute version of the SF-36v2 health survey. Percentage of 
responders following 8-weeks of treatment (observed cases) with levomilnacipran 
SR or placebo were compared for each individual health domain and the Physical 
(PCS) and Mental (MCS) Component Summary scores based on individual patient-
level responder criteria for minimally important differences. Estimates of odds 
ratios, 95% confidence intervals and p-values were from a logistic regression model 
with study and treatment as factors, baseline score as covariate and a study-by-
treatment interaction term. Results: Compared with placebo-treated patients, 
a greater percentage of patients who were treated with levomilnacipran SR were 
considered as responders. Homogeneity of OR could be assumed for the individual 
health domains and component summary scores except for the Bodily Pain scale 
(study-by-treatment interaction p-value= 0.0123). Pooled OR [95%-CI] for being a 
responder were as follows: MCS= 1.705 [1.292-2.250]; PCS= 1.285 [0.972-1.700]; General 
Health= 2.324 [1.763-3.064]; Social Functioning= 1.698 [1.295-2.226]; Vitality= 1.608 
[1.250-2.068]; Mental Health= 1.579 [1.203-2.072]; Role-Emotional= 1.453 [1.121-1.882]; 
Physical Functioning= 1.382 [1.032-1.850]; and Role-Physical= 1.341 [1.005-1.788]. All 
OR (except PCS) were statistically significant (p< 0.05). cOnclusiOns: Compared 
with placebo, patients who are treated with levomilnacipran SR are more likely to 
achieve meaningful improvement in multiple domains of health as measured by 
the SF-36 Health Survey.
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